Mirum Pharmaceuticals, Inc. (MIRM)


Stock Price Forecast

April 23, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Mirum Pharmaceuticals, Inc. chart...

About the Company

We do not have any company description for Mirum Pharmaceuticals, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

198

Exchange

Nasdaq

$32M

Total Revenue

198

Employees

$1B

Market Capitalization

-6.15

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MIRM News

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

2d ago, source:

FDA approved Mirum Pharmaceuticals' Limvarli for treatment of cholestatic pruritus in patients with PFIC. Learn why I rate ...

Analyst Ratings For Mirum Pharmaceuticals

7d ago, source:

Across the recent three months, 9 analysts have shared their insights on Mirum Pharmaceuticals (NASDAQ:MIRM), expressing a ...

Stifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy Recommendation

7d ago, source: Fintel on MSN

Fintel reports that on April 17, 2024, Stifel initiated coverage of Mirum Pharmaceuticals (NasdaqGM:MIRM) with a Buy ...

Mirum Pharmaceuticals Inc MIRM

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy

1mon ago, source: Hosted on MSN

Wednesday, The FDA approved Mirum Pharmaceuticals Inc’s (NASDAQ:MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients five years of age and older with progressive ...

Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares

1mon ago, source: Yahoo Finance

Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals Inc (NASDAQ:MIRM), executed a sale of 4,303 shares in the company on March 25, 2024, according to a recent SEC Filing.

Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughs

8d ago, source:

Dae Gon Ha, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Mirum Pharmaceuticals (MIRM). Dae Gon Ha has given his Buy ...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14d ago, source: Stockhouse

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of ...

Mirum Pharmaceuticals Inc MIRM

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mirum Pharmaceuticals Inc (MIRM)

6d ago, source: Investing

View the MIRM option chain and compare options of Mirum Pharmaceuticals Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...